Newswise — ARLINGTON, Va., December 12, 2019 — The American Society for Radiation Oncology (ASTRO) applauded the U.S. Senate for voting today to confirm radiation oncologist Stephen Hahn, MD, FASTRO, as the next Commissioner of the Food and Drug Administration (FDA).
“We applaud the U.S. Senate for confirming Dr. Stephen Hahn as the nation’s next Commissioner of the Food and Drug Administration. Dr. Hahn’s impressive background as a triple board-certified physician in medicine, medical oncology and radiation oncology coupled with his broad administrative experiences will allow him to ably lead the thousands of career professionals charged with ensuring U.S. consumer protection and public health,” said Theodore L. DeWeese, MD, FASTRO, Chair of the ASTRO Board of Directors. “Our support and respect for Dr. Hahn is based on his proven commitment to patients, science-based decision-making, and consumer health and safety. We look forward to his leadership as he steps into this critically important role as FDA Commissioner.”
The American Society for Radiation Oncology (ASTRO) is the world’s largest radiation oncology society, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology • Biology • Physics, Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, RT Answers; and created the nonprofit foundation Radiation Oncology Institute. To learn more about ASTRO, visit our website, sign up to receive our news and follow us on our blog, Facebook, Twitter and LinkedIn.